Fig 2. Changes in the proportion of Y93H RAV in 4cases with breakthrough or relapse.

Deep sequencing was performed in 4 patients with relapse (a) or breakthrough (b, c, d) to quantify the proportion of Y93H RAV against the Y93 wild type. In two cases, PR therapy was continued up to 24 wks after stopping SMV (b and c). The proportion of Y93H RAV decreased during SMV/PR therapy and at the time of breakthrough/relapse compared to baseline but recovered to the baseline level at follow up. PR therapy; pegylated interferon plus ribavirin therapy, SMV/PR therapy; Simeprevir plus pegylated interferon / ribavirin therapy